The purpose of this study is to compare the difference between tolterodine prolonged release (PR) and propiverine in efficacy as assessed by the AUM and to show that tolterodine PR is similar to propiverine with respect to micturition chart variables and safety profile.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
41
Two week washout period followed by propiverine 20 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to tolterodine PR 4 mg capsule daily for 1 week.
Two week washout period followed by tolterodine PR 4 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to propiverine 20 mg capsule daily for 1 week.
Pfizer Investigational Site
Seoul, South Korea
Parameters of detrusor activity, occurring throughout the duration of comparable AUM
Time frame: 28 days
Number of pads used per 24 hours
Time frame: 28 days
Urge Incontinence
Time frame: 28 days
Number of urgency episodes
Time frame: 28 days
Number of micturitions per 24 hours
Time frame: 28 days
Volume voided per micturition
Time frame: 28 days
Patient's perception of bladder condition
Time frame: 28 days
Patient's perception of treatment benefit
Time frame: 28 days
Patient's perception of urgency
Time frame: 28 days
The occurrences of adverse events and withdrawals and changes in laboratory variables over each 1-week treatment period.
Time frame: 42 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.